- Home
- ACDC vs PHVS Comparison
ACDC vs PHVS Comparison
Compare ACDC & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACDC
- PHVS
- Stock Information
- Founded
- ACDC 2014
- PHVS 2015
- Country
- ACDC United States
- PHVS Switzerland
- Employees
- ACDC N/A
- PHVS N/A
- Industry
- ACDC Oilfield Services/Equipment
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- ACDC Energy
- PHVS Health Care
- Exchange
- ACDC Nasdaq
- PHVS Nasdaq
- Market Cap
- ACDC 1.1B
- PHVS 980.3M
- IPO Year
- ACDC 2022
- PHVS 2021
- Fundamental
- Price
- ACDC $7.44
- PHVS $18.60
- Analyst Decision
- ACDC Hold
- PHVS Buy
- Analyst Count
- ACDC 5
- PHVS 6
- Target Price
- ACDC $7.10
- PHVS $37.17
- AVG Volume (30 Days)
- ACDC 932.3K
- PHVS 35.9K
- Earning Date
- ACDC 08-07-2025
- PHVS 08-13-2025
- Dividend Yield
- ACDC N/A
- PHVS N/A
- EPS Growth
- ACDC N/A
- PHVS N/A
- EPS
- ACDC N/A
- PHVS N/A
- Revenue
- ACDC $2,209,700,000.00
- PHVS N/A
- Revenue This Year
- ACDC N/A
- PHVS N/A
- Revenue Next Year
- ACDC $0.09
- PHVS N/A
- P/E Ratio
- ACDC N/A
- PHVS N/A
- Revenue Growth
- ACDC N/A
- PHVS N/A
- 52 Week Low
- ACDC $3.83
- PHVS $11.51
- 52 Week High
- ACDC $10.70
- PHVS $25.50
- Technical
- Relative Strength Index (RSI)
- ACDC 43.60
- PHVS 60.00
- Support Level
- ACDC $7.56
- PHVS $16.72
- Resistance Level
- ACDC $8.49
- PHVS $17.53
- Average True Range (ATR)
- ACDC 0.75
- PHVS 0.93
- MACD
- ACDC -0.28
- PHVS 0.07
- Stochastic Oscillator
- ACDC 6.86
- PHVS 92.86
About ACDC ProFrac Holding Corp.
ProFrac Holding Corp is engaged in providing hydraulic fracturing, completion services, and other complementary products and services to upstream oil and gas companies engaged in the exploration and production of North American unconventional oil and natural gas resources. Its operations are focused in West Texas, East Texas/Louisiana, South Texas, Oklahoma, Uinta, and Appalachian. The company operates in three segments: Stimulation Services, Proppant Production, and Manufacturing. Stimulation services, which generate the majority of the revenue for the company operate a fleet of mobile hydraulic fracturing units and other auxiliary equipment that generates revenue by providing stimulation services.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.